Does Hydroxyzine Help Decrease Nausea and Vomiting?
Yes, hydroxyzine can be effective for reducing nausea and vomiting, though it is not a first-line agent and should be reserved for specific clinical scenarios where primary antiemetics have failed or as an adjunct to other therapies.
Evidence-Based Positioning
The FDA drug label confirms that hydroxyzine has demonstrated antiemetic effects through both apomorphine and veriloid testing, with clinical effects typically noted within 15-30 minutes of oral administration 1. However, its role in clinical practice guidelines is limited and context-specific.
Clinical Context and Appropriate Use
For Opioid-Induced Pruritus (Not Primary Antiemetic Use)
The NCCN Adult Cancer Pain Guidelines (2019) mention hydroxyzine specifically for opioid-induced pruritus, where it may be administered by mouth or intramuscular injection 2. In this same guideline's section on nausea and vomiting management, hydroxyzine is notably absent from the recommended antiemetic agents, which instead prioritize:
- Phenothiazines (prochlorperazine, thiethylperazine)
- Dopamine antagonists (metoclopramide, haloperidol)
- 5-HT3 antagonists (ondansetron, granisetron)
- Olanzapine
- Corticosteroids
For Mast Cell Activation Syndrome
The AAAAI Mast Cell Disorders Guidelines (2019) note that cyproheptadine (a related sedating H1 antihistamine with antiserotonergic activity) "might help gastrointestinal symptoms" including nausea, suggesting a potential role for sedating antihistamines in this specific population 3.
Supporting Research Evidence
A 2024 retrospective study of 647 female surgical patients found that prophylactic hydroxyzine 25 mg significantly reduced postoperative nausea and vomiting (PONV) incidence on the day of surgery (34.8% vs 57.0%, p=0.002) compared to no prophylaxis 4. A 1981 randomized trial demonstrated that intramuscular hydroxyzine 100 mg was superior to droperidol 2.5 mg for preventing post-anesthesia nausea, retching, or vomiting (10% vs 44% incidence) 5.
Practical Algorithm for Use
Consider hydroxyzine when:
- Second-line or adjunctive therapy: First-line agents (5-HT3 antagonists, dopamine antagonists, dexamethasone) have been tried without adequate response
- Dual indication: Patient has both nausea AND pruritus (particularly opioid-induced)
- Anxiety-related nausea: Patient has significant anxiety component contributing to symptoms
- Mast cell disorders: Suspected or confirmed MCAS with gastrointestinal symptoms
Dosing:
- Oral or IM: 25-100 mg every 6-8 hours as needed
- Start with 25 mg in elderly or sedation-prone patients
Critical Caveats
Sedation Profile
Hydroxyzine causes significant sedation and delayed return of hand-eye coordination 5. This limits its utility in outpatient settings or when alertness is required.
Anticholinergic Effects
As a first-generation H1 antihistamine with anticholinergic properties, hydroxyzine can cause cognitive decline, particularly in elderly patients 3. This is a serious concern that should limit its use in geriatric populations.
Not Guideline-Recommended as Primary Antiemetic
Despite its antiemetic properties, hydroxyzine does not appear in the primary treatment algorithms of major antiemetic guidelines (NCCN Palliative Care 2016, ASCO Antiemetics 2017, ERAS guidelines) 6, 7. These guidelines consistently prioritize 5-HT3 antagonists, NK-1 antagonists, dopamine antagonists, and corticosteroids.
QT Prolongation Risk
The FDA label warns that hydroxyzine overdose may cause QT prolongation and Torsade de Pointes, requiring ECG monitoring in overdose situations 1. Use caution in patients with cardiac risk factors.
Bottom Line
Hydroxyzine has antiemetic properties but should not be used as a first-line agent for nausea and vomiting. Reserve it for situations where standard antiemetics are inadequate, when dual treatment of nausea and pruritus is needed, or in specific populations like mast cell disorders. The sedation and anticholinergic burden make it particularly unsuitable for elderly patients or those requiring alertness. When nausea persists despite hydroxyzine, reassess the underlying cause and escalate to guideline-recommended multimodal regimens using 5-HT3 antagonists, NK-1 antagonists, dopamine antagonists, and corticosteroids 2.